Ipilimumab
Ipilimumab is a monoclonal antibody directed against the cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), which is one of the checkpoints that regulates the immune system.
As a single agent, ipilimumab is approved for use in melanoma. It is used in combination with nivolumab for many other indications.
Provider Resources
